In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays
Authors:
Open Access
- 8 April 2023
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (6) , 1493-1502
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 27 references indexed in Scilit:
- Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalenceJournal of Thrombosis and Haemostasis, 2019
- Practical aspects of extended half-life products for the treatment of haemophiliaTherapeutic Advances in Hematology, 2018
- In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agentsJournal of Thrombosis and Haemostasis, 2018
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia ANew England Journal of Medicine, 2016
- Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectivenessJournal of Thrombosis and Haemostasis, 2013
- Coagulation procofactor activation by factor XIaJournal of Thrombosis and Haemostasis, 2010
- Characterization of Novel Forms of Coagulation Factor XIaJournal of Biological Chemistry, 2008
- Activation of factor VIII and mechanisms of cofactor actionBlood Reviews, 2004
- Calibrated Automated Thrombin Generation Measurement in Clotting PlasmaPathophysiology of Haemostasis and Thrombosis, 2003